Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Upgrade Now
NasdaqGS - Nasdaq Real Time Price USD

Syndax Pharmaceuticals, Inc. (SNDX)

Compare
12.97
+0.96
+(7.99%)
At close: April 2 at 4:00:00 PM EDT
12.33
-0.64
(-4.93%)
Pre-Market: 4:05:50 AM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
23,680
23,680
--
--
139,709
Cost of Revenue
826
826
--
--
--
Gross Profit
22,854
22,854
--
--
--
Operating Expense
362,526
362,526
229,954
151,757
113,489
Operating Income
-339,672
-339,672
-229,954
-151,757
26,220
Net Non Operating Interest Income Expense
21,161
21,161
20,955
2,735
-1,496
Other Income Expense
-247
-247
-361
-316
202
Pretax Income
-318,758
-318,758
-209,360
-149,338
24,926
Net Income Common Stockholders
-318,758
-318,758
-209,360
-149,338
24,926
Diluted NI Available to Com Stockholders
-318,758
-318,758
-209,360
-149,338
24,926
Basic EPS
-3.72
--
-2.98
-2.46
0.48
Diluted EPS
-3.72
--
-2.98
-2.46
0.48
Basic Average Shares
85,622.07
--
70,370.52
60,760.91
52,064.81
Diluted Average Shares
85,622.07
--
70,370.52
60,760.91
52,064.81
Total Operating Income as Reported
-339,672
-339,672
-229,954
-151,757
26,220
Total Expenses
363,352
363,352
229,954
151,757
113,489
Net Income from Continuing & Discontinued Operation
-318,758
-318,758
-209,360
-149,338
24,926
Normalized Income
-318,758
-318,758
-209,360
-149,338
24,926
Interest Income
26,090
26,090
21,163
5,872
403
Interest Expense
4,929
4,929
208
3,137
1,899
Net Interest Income
21,161
21,161
20,955
2,735
-1,496
EBIT
-313,829
-313,829
-209,152
-146,201
26,825
EBITDA
-313,821
-313,821
-209,140
-146,168
26,868
Reconciled Cost of Revenue
826
826
--
--
--
Reconciled Depreciation
8
8
12
33
43
Net Income from Continuing Operation Net Minority Interest
-318,758
-318,758
-209,360
-149,338
24,926
Normalized EBITDA
-313,821
-313,821
-209,140
-146,168
26,868
12/31/2021 - 3/2/2016

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

KURA Kura Oncology, Inc.
6.52
+2.19%
 
BCYC Bicycle Therapeutics plc
8.05
+2.55%
 
DAWN Day One Biopharmaceuticals, Inc.
7.97
+4.73%
 
MRUS Merus N.V.
43.01
+8.61%
 
KYMR Kymera Therapeutics, Inc.
26.36
+4.46%
 
IDYA IDEAYA Biosciences, Inc.
16.35
+10.70%
 
RVMD Revolution Medicines, Inc.
34.60
+2.91%
 
AGIO Agios Pharmaceuticals, Inc.
28.44
+3.80%
 
ETNB 89bio, Inc.
7.19
+5.81%
 
NUVL Nuvalent, Inc.
70.46
+3.62%